The FDA is condemning children to death by refusing to allow them access to experimental cancer treatments, even though it has the authority to grant such access to terminal patients who have not responded to conventional treatment. Six years ago, 10-year-old Braiden was enrolled in a clinical trial for his incurable brain tumor. The “experimental” drug Antineoplaston (ANP) was the sole treating agent. He went into full remission, and suffered no toxic side effects. An MRI recently revealed Braiden’s tumor has reoccurred. The FDA is now refusing to allow Braiden to go back on ANP even though the treatment has already proven its efficacy through his previous remission. Many other terminal patients are also being prevented from accessing ANP.